Cargando…

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

Treatment with monoclonal antibody specific for cytotoxic T lymphocyte–associated antigen 4 (CTLA-4), an inhibitory receptor expressed by T lymphocytes, has emerged as an effective therapy for the treatment of metastatic melanoma. Although subject to debate, current models favor a mechanism of activ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simpson, Tyler R., Li, Fubin, Montalvo-Ortiz, Welby, Sepulveda, Manuel A., Bergerhoff, Katharina, Arce, Frederick, Roddie, Claire, Henry, Jake Y., Yagita, Hideo, Wolchok, Jedd D., Peggs, Karl S., Ravetch, Jeffrey V., Allison, James P., Quezada, Sergio A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Rockefeller University Press 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754863/ https://www.ncbi.nlm.nih.gov/pubmed/23897981 http://dx.doi.org/10.1084/jem.20130579

Ejemplares similares

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
por: Arce Vargas, Frederick, et al.
Publicado: (2018)

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
por: Arce Vargas, Frederick, et al.
Publicado: (2017)

A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies
por: Li, Fubin, et al.
Publicado: (2012)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
por: Curran, Michael A., et al.
Publicado: (2011)

Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
por: Quezada, Sergio A., et al.
Publicado: (2008)

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
por: Quezada, S A, et al.
Publicado: (2013)

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
por: Peggs, Karl S., et al.
Publicado: (2009)

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B., et al.
Publicado: (2013)

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B, et al.
Publicado: (2013)

Anti–CTLA-4 therapy requires an Fc domain for efficacy
por: Ingram, Jessica R., et al.
Publicado: (2018)

Emerging options for the treatment of melanoma – focus on ipilimumab
por: Roddie, Claire, et al.
Publicado: (2014)

The role of Fc–FcγR interactions in IgG-mediated microbial neutralization
por: Bournazos, Stylianos, et al.
Publicado: (2015)

The Antitumor Activities of Anti-CD47 Antibodies Require Fc-FcγR interactions
por: Osorio, Juan C., et al.
Publicado: (2023)

Anti-CD11b antibody treatment suppresses the osteoclast generation, inflammatory cell infiltration, and autoantibody production in arthritis-prone FcγRIIB-deficient mice
por: Ohtsuji, Mareki, et al.
Publicado: (2018)

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
por: Fan, Xiaozhou, et al.
Publicado: (2014)

The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy
por: Uchida, Junji, et al.
Publicado: (2004)

The role of IgG Fc receptors in antibody-dependent enhancement
por: Bournazos, Stylianos, et al.
Publicado: (2020)

Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy
por: Sato, Yosuke, et al.
Publicado: (2022)

Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation
por: Shafat, Manar S., et al.
Publicado: (2020)

T Cell–specific Ablation of Fas Leads to Fas Ligand–mediated Lymphocyte Depletion and Inflammatory Pulmonary Fibrosis
por: Hao, Zhenyue, et al.
Publicado: (2004)

Refusing to TAP out: 16 new human TEIPPs identified
por: Gigoux, Mathieu, et al.
Publicado: (2018)

Inducing Tumor Immunity through the Selective Engagement of Activating Fcγ Receptors on Dendritic Cells
por: Kalergis, Alexis M., et al.
Publicado: (2002)

Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
por: Quezada, Sergio A., et al.
Publicado: (2010)

Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors
por: Kaneko, Yoshikatsu, et al.
Publicado: (2006)

Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection
por: Bournazos, Stylianos, et al.
Publicado: (2020)

Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines
por: Srinivasan, Roopa, et al.
Publicado: (2004)

Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
por: Zamarin, Dmitriy, et al.
Publicado: (2014)

Immunotherapy and the belly of the beast
por: Merghoub, Taha, et al.
Publicado: (2014)

Combined IL-21–primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient
por: Chapuis, Aude G., et al.
Publicado: (2016)

CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumors
por: Zappasodi, Roberta, et al.
Publicado: (2021)

(64)Cu-DOTA-Anti-CTLA-4 mAb Enabled PET Visualization of CTLA-4 on the T-Cell Infiltrating Tumor Tissues
por: Higashikawa, Kei, et al.
Publicado: (2014)

Genetic Modifiers of Systemic Lupus Erythematosus in FcγRIIB(−/−) Mice
por: Bolland, Silvia, et al.
Publicado: (2002)

Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
por: Vazquez-Lombardi, Rodrigo, et al.
Publicado: (2017)

CTLA4 depletes T cell endogenous and trogocytosed B7 ligands via cis-endocytosis
por: Xu, Xiaozheng, et al.
Publicado: (2023)

Direct comparisons of T cell costimulation and checkpoint blockade in the setting of tumor-targeted monoclonal antibody therapy
por: Khalil, Danny, et al.
Publicado: (2015)

Shared cancer neoantigens: Making private matters public
por: Klebanoff, Christopher A., et al.
Publicado: (2018)

The many faces of the anti-COVID immune response
por: Vardhana, Santosha A., et al.
Publicado: (2020)

CTLA4-Mediated Immunosuppression in Glioblastoma is Associated with the Infiltration of Macrophages in the Tumor Microenvironment
por: Guan, Xiudong, et al.
Publicado: (2021)

Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
por: Zhou, Yifan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sj2q16cfpisgd2u96s71ajtfaj